TEVA as equity financer????, page-93

@hodgsop: Since you asked to be corrected, let me tell you you are wrong.
From your quote "....FDA prevents any detail data being disseminated in order to maintain the integrity of a phase 3 trial", you are telling yourself that the FDA would allow detail data to be known to Teva and/or Mesoblast but not to others, and that still would maintain the integrity of the phase 3 trial??? Seriously?????

I think the negative posters here have gotten to you, what with their half baked knowledge about "interim results", "surrogate endpoints", blah blah blah. They seem to be more knowledgeable than the researchers, SI and all the doctors, don't they? Perhaps they have degrees in Public Health from the University of Tomfoolery.

Listen, I have already posted many times on this board about what a double-blind, randomized, Sham-procedure controlled study (which the CHF study is) entails and most everyone here still keep falling for the nonsense propagated by the band of posters who have come out to "rescue" shareholders.

Jeez!